They Already Ruined Cannabis. Now Psychedelics Are Next.

The clinical evidence is real. The valuations are not. Compass Pathways: $560 million market cap, zero revenue. MindMed: up to $2 billion, zero revenue. Even Ozempic lost half its value with $49 billion in real sales. When this bubble pops, the casualties won’t be on Wall Street. They’ll be the patients this medicine was supposed to reach.

The clinical evidence for psychedelic-assisted therapy is real, it is growing, and it matters. In the past five years, rigorously designed trials have shown that psilocybin can produce rapid and durable reductions in depressive symptoms that conventional antidepressants often cannot match. 

A dose-response meta-analysis of randomized placebo-controlled trials published in the Journal of Affective Disorders confirmed short-term efficacy for major depressive disorder. A VA-funded pilot study found that 60% of military veterans with severe treatment-resistant depression met response criteria three weeks after a single 25 mg dose, with 40% still in remission at twelve weeks—in a population that had failed multiple prior treatments. 

A Phase 2 trial of COMP360 psilocybin for PTSD showed rapid, durable symptom improvement lasting up to 12 weeks, with no serious adverse events, offering a potential breakthrough in a field with just two FDA-approved medications and persistently high dropout rates from trauma-focused therapy.  

In Germany, the first compassionate-use psilocybin therapy program launched in 2026 for patients with treatment-resistant depression. In the Czech Republic, lawmakers approved therapeutic psilocybin use for severe depression. In New Zealand, the first authorized prescriber began administering clinical doses in 2025.

For people living with conditions that resist everything else in the pharmacological toolkit, psychedelic therapy represents a genuinely novel mechanism—one that works through neuroplasticity, through the disruption of rigid default-mode network patterns, through the creation of psychological flexibility that allows patients to process trauma and break free from depressive loops. 

The need for legal, regulated access to these therapies is not speculative. It is clinical. It is urgent. And it is precisely because these substances have so much potential that the financial ecosystem building up around them demands scrutiny—not to undermine the science, but to protect it.

The Gap Between Science and Spreadsheets

I’m curious about how big this market could actually get. I pulled market-size estimates from ten research firms as of early 2026. For the base year alone—what the psychedelic therapeutics market is supposedly worth right now—estimates ranged from $603 million (Fact.MR) to $4.51 billion (Data Bridge, for the U.S. alone). That’s a sevenfold disagreement about the present. 

The forward projections fan wider: $4.2 billion by 2030 (Grand View Research), $9.6 billion by 2032 (Coherent Market Insights), $11 billion by 2034 (Precedence Research), $12.3 billion by 2035 (Research Nester). A 2021 report from Data Bridge projected $6.86 billion by 2027. We’re in 2026. That number exists nowhere outside the PDF.

Meanwhile, the only functioning regulated psilocybin market in the United States—Oregon’s Psilocybin Services program, launched in 2023, has generated approximately $1.7 million in cumulative revenue over three years, while roughly a third of its licensed service centers have closed. The state had to tap $3.1 million from its general fund to keep the regulatory program operational. 

The Ozempic Check

I want to hold the psilocybin sector’s financial profile against a drug that worked commercially, clinically, at a global scale, and see what it teaches us about what separates market speculative behavior from real-life value.

Novo Nordisk’s semaglutide—the molecule behind Ozempic and Wegovy—is the most successful pharmaceutical story of the past decade. FDA approval for diabetes came in 2017 after extensive Phase 3 trials. Approval for obesity followed in 2021. Revenue went from $21.3 billion in 2021 to $48.6 billion in 2025. The semaglutide franchise alone generated roughly $33 billion last year. Net profits in 2024 were approximately $14.6 billion. The company is spending $9.5 billion this decade on new production capacity in a single Danish town.

This is what a pharmaceutical blockbuster looks like when the science is proven, the trials are complete, the FDA has approved the product, 38 million Americans are in the patient base, the reimbursement infrastructure exists, and the revenue is real. 

Even with all of that, Novo Nordisk’s stock dropped more than 55% from its 52-week high in the past year. Competition from Eli Lilly, pricing pressure from government negotiations, and market saturation among patients who can afford $1,000-a-month drugs deflated even this juggernaut. The company lowered its guidance four times in 2025.

If the most successful drug franchise of the 2020s can lose half its market value despite $49 billion in annual revenue, what exactly is supporting the valuations of psychedelic companies that have never generated a dollar of commercial revenue?

The Valuation Question

COMPASS Pathways: market cap of approximately $560 million. Trailing revenue: zero. Net loss: nearly $288 million. Operating expenses of approximately $157 million per year. Every analyst forecasts $0 revenue for 2026. 

MindMed (now Definium Therapeutics): market cap $1.5–2 billion. Revenue: zero. Quarterly net loss: $42.7 million. Cash runway into 2027 only if current burn rates hold. 

The Valuation Gap: Zero Revenue, Billion-Dollar Market Caps

MindMed (Definium Therapeutics)

Quarterly Net Loss

$42.7M

Cash Runway

Into 2027 only if burn rates hold

Sources: Company filings. Every analyst forecasts $0 commercial revenue for COMPASS in 2026.

Atai Life Sciences merged with Beckley Psytech after a 40% single-day crash when a trial failed. Cybin, now Helus, secured $500 million in financing but has no product anywhere near market.

In October 2025, AbbVie completed its acquisition of Gilgamesh Pharmaceuticals’ bretisilocin for up to $1.2 billion. Bretisilocin is a synthetic analog designed to retain psilocybin’s antidepressant mechanism while shortening and softening the psychedelic experience. It is, by design, a pill that Big Pharma can route through conventional channels—no facilitators, no service centers, no therapeutic relationship architecture.

Novo Nordisk’s success was built on a molecule backed by a decade of trials, regulatory approval, massive patient populations, and reimbursement infrastructure. AbbVie’s bet follows the same logic, but has nothing to do with psilocybin as the therapeutic community understands it. The question for the movement is whether the path to legalization and access runs through this kind of deal, or gets swallowed by it.

Compare this to cannabis at peak hype: Tilray’s 2018 market cap of $13.4 billion on $43 million in revenue was absurd. But there were revenues. A product was being sold to real people.

Too afraid of letting ancestral therapies lose, politicians, lobbyists, and regulators are making psilocybin climb the pharmaceutical Mount Everest when they should be allowing small producers to actually work with the substance in controlled humanized environments.

But what’s the point of creating the constraints necessary to form a unicorn that can bypass regulations with science if it’s only going to make millions of investors lose money? This looks like a trade for the few, losses for the many.

The cannabis movement taught us what happens when the people who write the rules are the people who profit from them: patients get priced out, small operators get crushed, communities of color absorb the costs of prohibition, and none of the benefits of legalization, and the plant’s therapeutic credibility gets buried.

In psychedelics, there’s an additional layer. Mazatec communities in Mexico have publicly rejected the commercialization of their ceremonial practices. Peru declared ayahuasca knowledge a cultural patrimony in 2008. Brazil restricted legitimate use to religious contexts. 

Meanwhile, corporate firms file patents on compounds derived from these very traditions—strategies that legal scholars have flagged as potentially covering practices in use for centuries. If legalization advances without benefit-sharing frameworks, without indigenous consent structures, and without market architectures that prevent the kind of consolidation that gutted cannabis, then the science’s promise will be captured before patients ever see it. That is not an anti-psychedelic position. It is the most pro-psychedelic position there is.

The Industry These Substances Deserve

A veteran with treatment-resistant depression who found remission after a single psilocybin session at a VA medical center: that is real. 

A PTSD patient in a COMP360 trial who engaged with traumatic material for the first time without retraumatization: that is real. 

A facilitator in Portland running a lean clinic at $900 a session and clearing $10,000 a month doing meaningful work: that is real. 

A multi-billion-dollar industry sustained by market research PDFs that disagree with each other by a factor of seven: that’s BS.

Stock valuations unmoored from any commercial activity: that’s BS. 

Lobbying infrastructure that precedes the market it claims to represent, and a $1.2 billion acquisition of a compound redesigned to bypass the very therapeutic model the movement promised: that’s BS.

Novo Nordisk built the greatest drug franchise of the decade on rigorous science and massive real-world demand, and still lost half its stock value in a year. The psychedelic sector lacks that foundation.

Science is too important to be gambled on a winner-takes-all bet. 

The patients who need these therapies are too important to be overlooked. The path forward is better legalization: evidence-governed, community-accountable, structurally resistant to capture, and honest about what we know and what we don’t. If the cannabis experience taught us anything, it’s that the worst thing that can happen to a medicine is for it to become a financial instrument before it becomes accessible to the people who need it.

This article is reported analysis based on publicly available clinical trial data, SEC filings, institutional market research and on-the-record journalism. Financial figures reflect information available at time of publication and are subject to change. High Times does not endorse or encourage illegal activity of any kind.